Old Web
English
Sign In
Acemap
>
authorDetail
>
Oliver G. Ottmann
Oliver G. Ottmann
University of Würzburg
Blinatumomab
Medicine
Minimal residual disease
Adult Acute Lymphoblastic Leukemia
Transplantation
2
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
study of blinatumomab in patients with MRD in B-lineage ALL Long-term follow-up of hematologic relapse-free survival in a phase 2
2012
Michael Kneba
Peter Kufer
Patrick Baeuerle
Dirk Nagorsen
Margit Schmidt
Hermann Einsele
Gert Riethmüller
Markus Schaich
Monika Brüggemann
Oliver G. Ottmann
Svenja Neumann
Heinz A. Horst
Thorsten Raff
Andreas Viardot
S Topp
Gerhard Zugmaier
Evelyn Degenhard
Marie-Elisabeth Goebeler
Show All
Source
Cite
Save
Citations (0)
Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.
2008
Blood
Max S. Topp
Nikola Goekbuget
Peter Kufer
Gerhard Zugmaier
Evelyn Degenhard
Svenja Neumann
Heinz A Horst
A. Viardot
Mathias Schmid
Oliver G. Ottmann
Margit Schmidt
Carsten Reinhardt
Patrick A Baeuerle
Dirk Nagorsen
Dieter Hoelzer
Ralf Bargou
Show All
Source
Cite
Save
Citations (25)
1